| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 500mg | |||
| 1g | |||
| Other Sizes |
| Targets |
TNKS1 ( IC50 = 6 nM ); TNKS2 ( IC50 = 72 nM ); ARTD1 ( IC50 = 19.1 μM ); ARTD2 ( IC50 = 39.4 μM )
MN-64 targets tankyrase 1 (TNKS1) and tankyrase 2 (TNKS2), enzymes that regulate the Wnt/β-catenin signaling pathway by promoting the degradation of AXIN. Inhibition of tankyrases stabilizes AXIN, leading to decreased β-catenin levels and inhibition of Wnt signaling. |
|---|---|
| ln Vitro |
MN-64 is a potent inhibitor of tankyrase 1, with IC50 values for TNKS1, TNKS2, ARTD1, and ARTD2 of 6 nM, 72 nM, 19.1 μM, and 39.4 μM, respectively. MN-64 efficiently inhibits STF luciferase activity at 200 nM and Wnt/β-catenin at 1 μM[1].
In vitro, MN-64 potently inhibits TNKS1 with an IC50 of 6 nM and TNKS2 with an IC50 of 72 nM. It effectively inhibits Wnt/β-catenin signaling at 1 µM and blocks STF luciferase activity at 200 nM in HEK293 cells containing a Wnt pathway reporter system. |
| ln Vivo |
In vivo studies for MN-64 are limited. As a research tool, it is used to study the Wnt/β-catenin pathway. Detailed in vivo efficacy data have not been published.
|
| Enzyme Assay |
The in vitro enzyme inhibition assay for MN-64 involves measuring the kinase activity of tankyrase 1 and 2 in the presence of the compound. The assay uses a peptide substrate and NAD+ as a co-substrate for the PARP activity of tankyrases. The incorporation of ADP-ribose is quantified, and the IC50 is determined.
|
| Cell Assay |
Cellular assays for MN-64 involve treating HEK293 cells that contain a Wnt pathway reporter system (STF reporter) with the compound. The inhibition of Wnt/β-catenin signaling is measured by assessing luciferase activity. The concentration required to inhibit STF activity (e.g., 200 nM) is determined.
|
| Animal Protocol |
In vivo animal studies for MN-64 are not well-documented. As a research compound, it may be evaluated in animal models of cancer, but specific protocols have not been published.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of MN-64 have not been extensively characterized. It has a molecular weight of 264.32 g/mol and a molecular formula of C18H16O2.
|
| Toxicity/Toxicokinetics |
Toxicity data for MN-64 are limited. It is a research-grade compound, and comprehensive toxicological evaluations have not been published.
|
| References | |
| Additional Infomation |
MN-64 is a research compound for studying tankyrase and Wnt/β-catenin signaling. It has not entered clinical trials. Its mechanism involves potent inhibition of tankyrase 1, leading to stabilization of AXIN and inhibition of Wnt/β-catenin signaling.
|
| Molecular Formula |
C18H16O2
|
|---|---|
| Molecular Weight |
264.324
|
| Exact Mass |
264.115
|
| Elemental Analysis |
C, 81.79; H, 6.10; O, 12.11
|
| CAS # |
92831-11-3
|
| Related CAS # |
92831-11-3
|
| PubChem CID |
2802462
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.152±0.06 g/cm3 (20 °C, 760 mmHg)
|
| Boiling Point |
389.8±42.0 °C (760 mmHg)
|
| Melting Point |
63-64 °C (ethanol)
|
| LogP |
4.583
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
20
|
| Complexity |
388
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1C2C(=CC=CC=2)OC(C2C=CC(C(C)C)=CC=2)=C1
|
| InChi Key |
PYTOHIUBXSJKQH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H16O2/c1-12(2)13-7-9-14(10-8-13)18-11-16(19)15-5-3-4-6-17(15)20-18/h3-12H,1-2H3
|
| Chemical Name |
2-(4-propan-2-ylphenyl)chromen-4-one
|
| Synonyms |
MN 64; MN-64; MN64
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~53 mg/mL (200.5~100 mM)
Ethanol: ~53 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.46 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.46 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (9.46 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7833 mL | 18.9165 mL | 37.8329 mL | |
| 5 mM | 0.7567 mL | 3.7833 mL | 7.5666 mL | |
| 10 mM | 0.3783 mL | 1.8916 mL | 3.7833 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
